Effects of recombinant factor VIIa in haemorrhagic complications of urological operations

Acta Haematologica

Volumn 109, Issue 3, 2003, Pages 158-160

  Michalska Krzanowska, Grazyna ^a   Sajdak, Renata ^a,b   Stasiak Pikuła, Elzbieta ^a  

^a Clinical Hospital No 2   (Poland)

^b ICU Clinical State Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ELECTROLYTE; FRESH FROZEN PLASMA; GELATIN; HETASTARCH; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLADDER MALFORMATION; BLEEDING; CASE REPORT; CLINICAL FEATURE; CRYOPRECIPITATE; ERYTHROCYTE TRANSFUSION; EXPERIENCE; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; INTUBATION; LABORATORY TEST; LOW DRUG DOSE; MALE; NEPHROLITHIASIS; PERCUTANEOUS NEPHROSTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE TUMOR; PROSTATECTOMY; SKIN ABSCESS; TREATMENT OUTCOME; TUMOR; UROLOGIC SURGERY;

ADULT; FACTOR VIIA; HUMANS; MALE; MIDDLE AGED; NEPHROSTOMY, PERCUTANEOUS; POSTOPERATIVE HEMORRHAGE; PROSTATECTOMY; RECOMBINANT PROTEINS; UROLOGIC SURGICAL PROCEDURES;

EID: 0037279213     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069292     Document Type: Article

References (11)

1. Rao LV, Rapaport SI: Factor VIIa-catalysed activation of factor X independent of tissue factor. Its possible significance for control of hemophilic bleeding by infused factor VIIa. Blood 1990;75:1069-1073.
2. Hoffman M, Monroe DM, Roberts HR: Human monocytes support factor X activation by factor VIIa, independent of tissue factor: Implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994;83:38-42.
3. Lindley CM, Sawyer WT, Macik BG: Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648.
4. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS: Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and potent inhibitor. Mayo Clin Proc 1994;69:641-644.
5. Bell BA, Birch K, Glazer S: Experience with recombinant factor VIIa in an infant hemophilia with inhibitors to FVII: C undergoing emergency central line placement. Am J Pediatr Hematol/Oncol 1993;15:77-79.
6. Hay CRM, Negier C, Ludlam CA: The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost 1997;79:1463-1467.
7. Santagostino E, Gringeri A, Mannuci PM: Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999;104:22-26.
8. Friederich PW, Geerdink MGF, Spataro M, Messelink EJ, Henny CP, Buller HR, Levi M: The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: The PROSE study. Blood Coagul Fibrinolysis 2000;11(suppl 1):129-132.
9. Pickard JD, Kirkpatrick PJ, Melsen T, Andreasen RB, Gelling L, Fryer T, Matthews J, Minhas P, Hutchinson PJ, Menon D, Downey SP, Kendall I, Clark J, Carpenter TA, Williams E, Persson L: Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 2000;11(suppl 1):117-120.
10. Liem A, Biesma DH, Ernst SM, Schepens AA: Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms. Thromb Haemost 1999;82:150-151.
11. Al Douri M, Shafi T, Al Khudairi D, Al Bodhari E, Black L, Akinwale N, Osdman Musa M, Al Homaidhi A, Al Fagih M, Borum Andreasen R: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrynolysis 2000; 11(suppl 1):121-127.